Invisalign and FDA Warning
Links shared publicly online about this topic
Most Recently Shared on April 26, 2012 at 12:01 pm By:
smartbrief.com — “The FDA issued new safety warning labels for Eli Lilly and Co.'s attention-deficit/hyperactivity disorder treatment Strattera, or atomoxetine, for people with serious heart conditions. The agency reviewed clinical trials and found that 5% to 10% of adults and children experienced increases in blood…” View full resource at smartbrief.com
Most Recently Shared on July 18, 2012 at 7:22 pm By:
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
Influenza A virus subtype H1N1
Dr. Palazzari started Lafayette Pediatrics and Internal Medicine in 2011. Originally from Minnesota, he received his undergraduate degree in Biology from Gustavus Adolphus College in St. Peter, MN. He attended the University of Minnesota Medical School where he earned his M.D. and was inducted into the Alpha Omega Alpha (AOA) Honor Society. In 2005, he completed a combined residency in Internal Medicine and Pediatrics at the University of North Carolina at Chapel Hill. Following residency, he worked as an Academic Hospitalist at UNC for a year, before moving to Colorado. Here, Dr. Palazzari worked at Broomfield Pediatrics and Internal Medicine, in Broomfield, CO, transforming it from a pediatrics-only clinic to a full Med/Peds clinic. He is board certified in both Pediatrics and Internal Medicine. Dr. Palazzari has courtesy staff privileges at The Children’s Hospital and admitting staff privileges at Avista Adventist Hospital and Exempla Good Samaritan Hospital. He is a fellow of the American Academy of Pediatrics (AAP) and a fellow of the American College of Physicians (ACP).